Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC Mutation

被引：19

作者：

de Cueto, A. ^{[1
,2
]}

Rodriguez, J. M. ^{[2
]}

Soriano, M. J. ^{[3
]}

Lopez-Cerero, L. ^{[1
,2
]}

Venero, J. ^{[3
]}

Pascual, A. ^{[1
,2
]}

机构：

[1] Univ Hosp Virgen Macarena, Dept Microbiol, Seville, Spain

[2] Univ Seville, Sch Med, Dept Microbiol, Seville, Spain

[3] Univ Hosp Virgen Macarena, Dept Internal Med, Seville, Spain

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2008年 / 46卷 / 04期

关键词：

D O I：

10.1128/JCM.02066-07

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The fatal outcome of levofloxacin treatment in a patient with bacteremic pneumonia caused by Streptococcus pneumoniae with a preexisting parC mutation is reported. Failure was due to the emergence of a gyrA mutation after 4 days of therapy. Problems encountered in detecting first-step mutation isolates are discussed.

引用

页码：1558 / 1560

页数：3

共 18 条

[1] Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005 [J].

Adam, Heather J. ;

Schurek, Kristen N. ;

Nichol, Kimberly A. ;

Hoban, Chris J. ;

Baudry, Trish J. ;

Laing, Nancy M. ;

Hoban, Daryl J. ;

Zhanel, George G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) :198-207

[2] Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J].

Allen, GP ;

Kaatz, GW ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2606-2614

[3]

[Anonymous], [No title captured]

[4] Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema [J].

Carlavilla, AB ;

López-Medrano, F ;

Chaves, F ;

Villena, V ;

Echave-Sustaeta, J ;

Aguado, JM .

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2005, 23 (05) :270-273

[5] Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy [J].

Croisier, DE ;

Etienne, M ;

Bergoin, E ;

Charles, PE ;

Lequeu, C ;

Piroth, L ;

Portier, H ;

Chavanet, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1699-1707

[6] Fluoroauinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain [J].

de la Campa, AG ;

Balsalobre, L ;

Ardanuy, C ;

Fenoll, A ;

Pérez-Trallero, E ;

Liñares, J .

EMERGING INFECTIOUS DISEASES, 2004, 10 (10) :1751-1759

[7] Antimicrobial resistance among Streptococcus pneumoniae in the United States:: Have we begun to turn the corner on resistance to certain antimicrobial classes? [J].

Doern, GV ;

Richter, SS ;

Miller, A ;

Miller, N ;

Rice, C ;

Heilmann, K ;

Beekmann, S .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (02) :139-148

[8] Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia [J].

Endimiani, A ;

Brigante, G ;

Bettaccini, AA ;

Luzzaro, F ;

Grossi, P ;

Toniolo, AQ .

BMC INFECTIOUS DISEASES, 2005, 5 (1)

[9] Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae:: A case-control study [J].

Ho, PL ;

Tse, WS ;

Tsang, KWT ;

Kwok, TK ;

Ng, TK ;

Cheng, VCC ;

Chan, RMT .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) :701-707

[10] Quinolone resistance among pneumococci: Therapeutic and diagnostic implications [J].

Low, DE .

CLINICAL INFECTIOUS DISEASES, 2004, 38 :S357-S362

← 1 2 →